BURLINGTON, Mass. and JERUSALEM, March 31, 2026
BrainsWay Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief’s Proliv™Rx neuromodulation system, marking a significant breakthrough in non-invasive treatment for major depressive disorder (MDD). The approval establishes Proliv™Rx as the first and only FDA-approved at-home neuromodulation device with Class III labeling, specifically indicated for adult patients who have not responded adequately to at least one antidepressant therapy, expanding access to innovative mental health treatment solutions.
FDA PMA Approval Validates At-Home Neuromodulation
The FDA PMA approval, the most rigorous regulatory pathway for medical devices, confirms the safety, efficacy, and clinical reliability of the Proliv™Rx system. This milestone represents a transformative shift in mental healthcare, as it enables patients to receive clinically validated treatment both at home and in clinical settings, reducing reliance on traditional in-clinic therapies.
The device is indicated for treatment-resistant depression, a condition affecting millions of patients worldwide who often face limited therapeutic options and diminished quality of life. By offering a non-pharmacological alternative, Proliv™Rx provides clinicians with a new tool to complement existing therapies, addressing a significant gap in mental health treatment.
This approval also highlights the FDA’s increasing support for digital health and neuromodulation technologies, particularly those that promote patient-centric care models and remote treatment delivery, which are becoming essential in modern healthcare systems.
Advertisement
Innovative Multi-Channel Brain Stimulation Technology
The Proliv™Rx system utilizes a wearable, non-invasive, multi-channel neuromodulation platform designed to stimulate multiple brain regions simultaneously, targeting neural pathways associated with mood regulation and cognitive function. This advanced approach differentiates it from traditional single-channel devices and enhances its potential to deliver more effective and consistent therapeutic outcomes.
The system is engineered for ease of use and patient convenience, allowing individuals to administer therapy in their own homes while maintaining clinical oversight. This capability is particularly valuable for patients who face barriers to accessing in-clinic treatments, such as geographic limitations, mobility challenges, or time constraints.
By integrating advanced neuroscience with wearable technology, Proliv™Rx represents a significant step forward in the evolution of precision neuromodulation therapies, enabling more personalized and accessible treatment options for patients with complex mental health conditions.
Strategic Impact on Mental Health Innovation
The FDA approval of Proliv™Rx also reinforces BrainsWay’s leadership in the neurostimulation and mental health technology space, complementing its existing Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. This development enables the company to offer a comprehensive treatment ecosystem, combining in-clinic and at-home therapies to address a broader patient population.
The ability to deliver treatment across multiple care settings reflects a broader industry trend toward integrated, technology-driven healthcare solutions, where innovation focuses on improving accessibility, scalability, and patient outcomes. As demand for mental health services continues to grow globally, solutions like Proliv™Rx are expected to play a critical role in addressing unmet clinical needs and expanding treatment capacity.
Furthermore, the approval validates BrainsWay’s strategic investment in Neurolief, demonstrating how collaboration, innovation, and regulatory success can drive meaningful advancements in patient care and commercial growth.
The FDA approval of Neurolief’s Proliv™Rx system marks a major milestone in the treatment of major depressive disorder, offering patients a safe, effective, and accessible neuromodulation therapy. By enabling at-home treatment and leveraging advanced multi-channel brain stimulation technology, this innovation represents a significant step forward in modern mental healthcare, reinforcing the growing impact of MedTech solutions in transforming patient outcomes.
Source: BrainsWay press release
